Blood News and Research

RSS

Sleep fragmentation, poor sleep quality associated with decline in executive function

A new study of older men found a link between poor sleep quality and the development of cognitive decline over three to four years.

1 Apr 2014

Young adults with cardiac risk factors have worse cognitive function in middle age

Young adults with such cardiac risk factors as high blood pressure and elevated glucose levels have significantly worse cognitive function in middle age, according to a new study by dementia researchers at UC San Francisco.

1 Apr 2014

Extreme summer heat in Montreal may have effect on early-term deliveries

When temperatures reach 32-C or higher over a period of four to seven days, the risk of early-term delivery is 27% higher than on typical summer days, according to a study led by Nathalie Auger of the University of Montreal's Department of Social and Preventive Medicine. The study involved data from 300,000 births that took place in Montreal between 1981 to 2010 with summer temperatures recorded by Environment Canada during this period. Auger is also affiliated with the university's CHUM Superhospital Research Centre.

1 Apr 2014

S. pneumoniae is commonest cause of paediatric CAP

Streptococcus pneumoniae is the predominant cause of community-acquired pneumonia among children in Belgium, with non-vaccine serotypes accounting for the majority of cases, a Belgian study shows.

31 Mar 2014

Rigorous blood pressure control could halve recurrent stroke risk

Ensuring that the blood pressure of stroke survivors is controlled at least three-quarters of the time may halve their risk of a recurrence, shows a secondary analysis of the VISP trial.

31 Mar 2014

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

rEVO Biologics Inc., a subsidiary of LFB SA, today announced the initiation of the Phase 3 clinical program for ATryn for the treatment of preeclampsia in pregnant women during the 24th to 28th week of pregnancy.

31 Mar 2014

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.

31 Mar 2014

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

31 Mar 2014

Bariatric surgery patients report better quality of life

A study by Cleveland Clinic researchers shows bariatric surgery is a highly effective and durable treatment for type 2 diabetes in obese patients, enabling nearly all surgical patients to be free of insulin and many to be free of all diabetic medications three years after surgery.

31 Mar 2014

NxStage Medical receives American Red Cross Northeast Chapter's Workplace Hero Award

NxStage Medical Inc., a leading manufacturer of home dialysis products, today announced the Company has been awarded the 2014 Workplace Hero Award by the Northeast Chapter of the American Red Cross.

31 Mar 2014

Enrollment commences for Daiichi Sankyo's ENSURE-AF multinational phase 3 study in NVAF patients

Daiichi Sankyo Company, Limited today announced that it has started enrolling patients into the ENSURE-AF multinational phase 3 study, which will evaluate the efficacy and safety of its investigational oral, once-daily direct factor Xa-inhibitor edoxaban compared to enoxaparin/warfarin for the prevention of stroke and other blood clot complications in patients with non-valvular atrial fibrillation (NVAF) undergoing electrical cardioversion (low-energy shocks to trigger normal heart rhythm).

31 Mar 2014

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C) compared to placebo in patients with high cholesterol.

31 Mar 2014

Genetic markers could help predict heart attack in patients with heart disease

Researchers at the Intermountain Medical Center Heart Institute in Salt Lake City have identified a biological process that may help physicians predict when someone with heart disease is likely to have a heart attack in the near future.

31 Mar 2014

Panasonic and KKR complete share purchase agreement

Panasonic Corporation ("Panasonic") and KKR, a leading global investment firm, today announced the completion of a share purchase agreement and a shareholders' agreement under which Panasonic and KKR have become joint partners of Panasonic Healthcare Co., Ltd. ("Panasonic Healthcare").

From PHC Europe B.V. 31 Mar 2014

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

EKOS Corporation, a BTG International group company, notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States.

31 Mar 2014

Researchers quantify proportion of adults potentially affected by updated 2014 BP recommendations

Applying the updated 2014 blood pressure (BP) guideline to the U.S. population suggests that nearly 6 million adults are no longer classified as needing hypertension medication, and that an estimated 13.5 million adults would now be considered as having achieved goal blood pressure, primarily older adults, according to a JAMA study released online to coincide with the 2014 American College of Cardiology Scientific Sessions.

31 Mar 2014

Newly identified protein markers have potential to contribute to better understanding of heart disease

Researchers at the Intermountain Medical Center Heart Institute in Murray, Utah, have discovered that elevated levels of two recently identified proteins in the body are inflammatory markers and indicators of the presence of cardiovascular disease.

31 Mar 2014

Mechanical circulatory assist device may have untapped potential in heart surgery patients, say physicians

The most frequently used mechanical circulatory assist device in the world may have untapped potential, physicians say.

31 Mar 2014

Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

Use of the drug aleglitazar, which has shown the ability to lower glucose levels and have favorable effects on cholesterol, did not reduce the risk of cardiovascular death, heart attack or stroke among patients with type 2 diabetes and recent heart attack or unstable angina, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions.

31 Mar 2014

Millions of US adults may no longer need blood pressure medication, study suggests

New guidelines that ease the recommended blood pressure could result in 5.8 million U.S. adults no longer needing hypertension medication, according to an analysis by Duke Medicine researchers.

31 Mar 2014

Blood News and Research

Sleep fragmentation, poor sleep quality associated with decline in executive function

Young adults with cardiac risk factors have worse cognitive function in middle age

Extreme summer heat in Montreal may have effect on early-term deliveries

S. pneumoniae is commonest cause of paediatric CAP

Rigorous blood pressure control could halve recurrent stroke risk

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

Bariatric surgery patients report better quality of life

NxStage Medical receives American Red Cross Northeast Chapter's Workplace Hero Award

Enrollment commences for Daiichi Sankyo's ENSURE-AF multinational phase 3 study in NVAF patients

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Genetic markers could help predict heart attack in patients with heart disease

Panasonic and KKR complete share purchase agreement

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

Researchers quantify proportion of adults potentially affected by updated 2014 BP recommendations

Newly identified protein markers have potential to contribute to better understanding of heart disease

Mechanical circulatory assist device may have untapped potential in heart surgery patients, say physicians

Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

Millions of US adults may no longer need blood pressure medication, study suggests

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News